Genomics-Driven Discovery of a Novel Glutarimide Antibiotic from Burkholderia gladioli Reveals an Unusual Polyketide Synthase Chain Release Mechanism.
Ioanna T NakouMatthew JennerYousef DashtiIsolda Romero-CanelonJoleen MasscheleinEshwar MahenthiralingamGregory L ChallisPublished in: Angewandte Chemie (International ed. in English) (2020)
A gene cluster encoding a cryptic trans-acyl transferase polyketide synthase (PKS) was identified in the genomes of Burkholderia gladioli BCC0238 and BCC1622, both isolated from the lungs of cystic fibrosis patients. Bioinfomatics analyses indicated the PKS assembles a novel member of the glutarimide class of antibiotics, hitherto only isolated from Streptomyces species. Screening of a range of growth parameters led to the identification of gladiostatin, the metabolic product of the PKS. NMR spectroscopic analysis revealed that gladiostatin, which has promising activity against several human cancer cell lines and inhibits tumor cell migration, contains an unusual 2-acyl-4-hydroxy-3-methylbutenolide in addition to the glutarimide pharmacophore. An AfsA-like domain at the C-terminus of the PKS was shown to catalyze condensation of 3-ketothioesters with dihydroxyacetone phosphate, thus indicating it plays a key role in polyketide chain release and butenolide formation.
Keyphrases
- cell migration
- cystic fibrosis
- end stage renal disease
- molecular docking
- endothelial cells
- newly diagnosed
- ejection fraction
- single cell
- magnetic resonance
- chronic kidney disease
- prognostic factors
- small molecule
- papillary thyroid
- high resolution
- fatty acid
- squamous cell carcinoma
- high throughput
- pseudomonas aeruginosa
- molecular dynamics
- genome wide
- gene expression
- mass spectrometry
- dna methylation
- lung function
- patient reported outcomes
- induced pluripotent stem cells
- solid state
- air pollution
- patient reported
- genome wide analysis